Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Molecular Templates, Inc is a biotechnology business based in the US. Molecular Templates shares (MTEM) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Templates employs 247 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.94|
|52-week range||$6.41 - $15.19|
|50-day moving average||$7.92|
|200-day moving average||$9.82|
|Wall St. target price||$15.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||15.80%|
|3 months (2021-04-30)||-4.49%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Revenue TTM||$17.9 million|
|Gross profit TTM||$-74,120,000|
|Return on assets TTM||-31.83%|
|Return on equity TTM||-114.17%|
|Market capitalisation||$409.5 million|
TTM: trailing 12 months
There are currently 1.6 million Molecular Templates shares held short by investors – that's known as Molecular Templates's "short interest". This figure is 0.9% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Molecular Templates shares can be evaluated.
Molecular Templates's "short interest ratio" (SIR) is the quantity of Molecular Templates shares currently shorted divided by the average quantity of Molecular Templates shares traded daily (recently around 262793.15525876). Molecular Templates's SIR currently stands at 5.99. In other words for every 100,000 Molecular Templates shares traded daily on the market, roughly 5990 shares are currently held short.
However Molecular Templates's short interest can also be evaluated against the total number of Molecular Templates shares, or, against the total number of tradable Molecular Templates shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Molecular Templates's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Molecular Templates shares in existence, roughly 30 shares are currently held short) or 0.0396% of the tradable shares (for every 100,000 tradable Molecular Templates shares, roughly 40 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Molecular Templates.
Find out more about how you can short Molecular Templates stock.
We're not expecting Molecular Templates to pay a dividend over the next 12 months.
Molecular Templates's shares were split on a 1:11 basis on 1 August 2017. So if you had owned 11 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Molecular Templates shares – just the quantity. However, indirectly, the new 1000% higher share price could have impacted the market appetite for Molecular Templates shares which in turn could have impacted Molecular Templates's share price.
Over the last 12 months, Molecular Templates's shares have ranged in value from as little as $6.41 up to $15.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Templates's is 1.2239. This would suggest that Molecular Templates's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Molecular Templates, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.